Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:45:18 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:FBIO from 2023-05-04 to 2024-05-03 - 104 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 16:01U:FBIONews ReleaseMustang Bio Announces Closing of $4 Million Public Offering
2024-05-01 16:02U:FBIONews ReleaseJourney Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
2024-04-29 20:00U:FBIONews ReleaseMustang Bio Announces Pricing of $4 Million Public Offering
2024-04-29 08:00U:FBIONews ReleaseAvenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
2024-04-25 08:31U:FBIONews ReleaseJourney Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
2024-04-24 07:31U:FBIONews ReleaseAvenue Therapeutics Announces Reverse Stock Split
2024-03-28 16:05U:FBIONews ReleaseFortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
2024-03-28 09:01U:FBIONews ReleaseMustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
2024-03-25 08:30U:FBIONews ReleaseAvenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
2024-03-22 08:30U:FBIONews ReleaseCheckpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
2024-03-21 16:01U:FBIONews ReleaseJourney Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
2024-03-18 16:05U:FBIONews ReleaseAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
2024-03-18 08:31U:FBIONews ReleaseJourney Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
2024-03-18 08:01U:FBIONews ReleaseCheckpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
2024-03-15 08:30U:FBIONews ReleaseJourney Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
2024-03-15 08:15U:FBIONews ReleaseAvenue Therapeutics Receives Positive Listing Determination from Nasdaq
2024-03-13 08:30U:FBIONews ReleaseJourney Medical Corporation to Participate in the 36th Annual ROTH Conference
2024-03-12 08:30U:FBIONews ReleaseFortress Biotech to Participate in 36th Annual ROTH Conference
2024-03-11 08:31U:FBIONews ReleaseJourney Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
2024-03-11 08:00U:FBIONews ReleaseAvenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
2024-03-07 07:30U:FBIONews ReleaseMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ralpha2-targeted CAR T-Cells in High-Grade Glioma
2024-03-04 08:30U:FBIONews ReleaseFortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
2024-02-22 08:30U:FBIONews ReleaseAvenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
2024-02-02 14:42U:FBIONews ReleaseLindsay Rosenwald ƒ ¢ ‚ € ‚ ™s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries
2024-01-29 08:01U:FBIONews ReleaseCheckpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
2024-01-11 08:31U:FBIONews ReleaseMustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
2024-01-11 08:16U:FBIONews ReleaseCheckpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
2024-01-11 08:00U:FBIONews ReleaseAvenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
2024-01-05 09:16U:FBIONews ReleaseAvenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
2024-01-05 08:30U:FBIONews ReleaseJourney Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
2024-01-04 08:31U:FBIONews ReleaseAvenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
2024-01-03 16:01U:FBIONews ReleaseFortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-01-02 16:06U:FBIONews ReleaseJourney Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
2024-01-02 08:31U:FBIONews ReleaseAvenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
2023-12-29 08:20U:FBIONews ReleaseFortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2023-12-11 08:30U:FBIONews ReleaseMustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
2023-12-06 08:30U:FBIONews ReleaseSentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics
2023-12-06 08:30U:FBIONews ReleaseCyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.
2023-12-06 08:01U:FBIONews ReleaseJourney Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
2023-12-05 08:30U:FBIONews ReleaseCheckpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
2023-12-01 08:31U:FBIONews ReleaseAvenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
2023-11-14 16:10U:FBIONews ReleaseFortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
2023-11-14 16:06U:FBIONews ReleaseMustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
2023-11-14 16:01U:FBIONews ReleaseFortress Biotech Announces Closing of $10.0 Million Public Offering
2023-11-13 17:01U:FBIONews ReleaseCheckpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
2023-11-13 16:05U:FBIONews ReleaseAvenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
2023-11-10 08:16U:FBIONews ReleaseFortress Biotech Announces Pricing of $10.0 Million Public Offering
2023-11-09 17:05U:FBIONews ReleaseFortress Biotech Announces Launch of Proposed Public Offering
2023-11-07 16:01U:FBIONews ReleaseJourney Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
2023-11-02 15:01U:FBIONews ReleaseAvenue Therapeutics Announces Closing of $5.0 Million Public Offering
2023-11-02 09:28U:FBIONews ReleaseMustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
2023-10-31 09:16U:FBIONews ReleaseAvenue Therapeutics Announces Pricing of $5.0 Million Public Offering
2023-10-31 08:30U:FBIONews ReleaseJourney Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023
2023-10-30 14:16U:FBIONews ReleaseMustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2023-10-26 12:30U:FBIONews ReleaseMustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2023-10-26 09:01U:FBIONews ReleaseMustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13R Ž ±2 ¢ € targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
2023-10-20 08:31U:FBIONews ReleaseJourney Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn ‚ ® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)
2023-10-18 08:31U:FBIONews ReleaseCheckpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer
2023-10-16 09:00U:FBIONews ReleaseFortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
2023-10-09 12:50U:FBIONews ReleaseFortress Biotech Announces Reverse Stock Split
2023-10-05 08:31U:FBIONews ReleaseFortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference
2023-10-02 12:54U:FBIONews ReleaseCheckpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
2023-09-21 08:30U:FBIONews ReleaseCheckpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
2023-09-07 08:30U:FBIONews ReleaseFortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference
2023-09-07 08:15U:FBIONews ReleaseMustang Bio to Participate in Upcoming September 2023 Investor Conferences
2023-09-06 08:30U:FBIONews ReleaseCheckpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
2023-09-06 08:00U:FBIONews ReleaseJourney Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza ‚ ® in South Korea and Other Asian Nations
2023-09-05 08:31U:FBIONews ReleaseAvenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
2023-08-16 08:01U:FBIONews ReleaseMustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
2023-08-14 16:16U:FBIONews ReleaseCheckpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
2023-08-14 16:06U:FBIONews ReleaseMustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
2023-08-14 16:02U:FBIONews ReleaseFortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
2023-08-10 16:16U:FBIONews ReleaseAvenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
2023-08-08 16:02U:FBIONews ReleaseJourney Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
2023-08-03 08:31U:FBIONews ReleaseFortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023
2023-08-03 08:01U:FBIONews ReleaseMustang Bio to Participate in Two August 2023 Investor Conferences
2023-08-02 16:02U:FBIONews ReleaseJourney Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023
2023-08-01 08:31U:FBIONews ReleaseAvenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
2023-07-31 08:31U:FBIONews ReleaseMustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
2023-07-31 08:00U:FBIONews ReleaseCheckpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
2023-07-27 08:31U:FBIONews ReleaseAvenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
2023-07-27 07:00U:FBIONews ReleaseCheckpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
2023-07-25 08:30U:FBIONews ReleaseAvenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
2023-07-19 08:30U:FBIONews ReleaseJourney Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023
2023-07-11 08:30U:FBIONews ReleaseJourney Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
2023-07-06 08:01U:FBIONews ReleaseMustang Bio Announces Participation in Upcoming Scientific Meetings
2023-07-03 08:00U:FBIONews ReleaseJourney Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of Jul
2023-06-29 08:01U:FBIONews ReleaseUrica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
2023-06-28 08:00U:FBIONews ReleaseCheckpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
2023-06-15 16:02U:FBIONews ReleaseMustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
2023-06-15 08:01U:FBIONews ReleaseHelocyte Announces $3.22 Million Grant from the National Cancer Institute ‚  for Triplex Phase 2 Clinical Trial Program
2023-06-13 08:31U:FBIONews ReleaseJourney Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects
2023-06-12 08:01U:FBIONews ReleaseMustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
2023-05-23 08:30U:FBIONews ReleaseCheckpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2023-05-22 16:02U:FBIONews ReleaseJourney Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
2023-05-19 16:01U:FBIONews ReleaseJourney Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023
2023-05-18 08:03U:FBIONews ReleaseMustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates
2023-05-15 16:16U:FBIONews ReleaseCheckpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
2023-05-15 16:02U:FBIONews ReleaseFortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
2023-05-12 16:05U:FBIONews ReleaseMustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
2023-05-12 08:31U:FBIONews ReleaseAvenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
2023-05-11 16:04U:FBIONews ReleaseMustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
2023-05-11 16:01U:FBIONews ReleaseJourney Medical Corporation Announces Postponement of First Quarter ‚  Financial Results Release and Conference Call
2023-05-04 09:00U:FBIONews ReleaseJourney Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023